ArticleLeukemia & lymphoma2022
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
Article in Leukemia & lymphoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Cutaneous Acral Presentation of Indolent Mantle Cell Lymphoma With Prominent Nail Involvement and Atypical Immunophenotype.Journal of cutaneous pathology · 2026Article
- Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.Blood advances · 2025Observational
- Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.Annals of hematology · 2025Article
- Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.Annals of hematology · 2025Article
- Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma.Journal of hematology · 2024Article
- Clinical and pathological characteristics of blastoid mantle cell lymphoma: a single institution experience.F1000Research · 2024Article
- EBV-Positive Pleomorphic Variant Transformation of CD5-Negative Mantle Cell Lymphoma: A Rare Case Report and Literature Review.Case reports in hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Funding
Abstract
Conventionally, mantle cell lymphoma (MCL) is an aggressive CD5-positive B-cell malignancy with poor prognosis and limited survival. However, a small subset of patients presents with indolent disease and can be managed on a 'watch and wait' approach. CD5-negative MCL has recently been recognized as a more favorable variant of MCL, but its clinical and biological implications remain ill-defined. We performed the most extensive review to-date of all reported cases of CD5-negative MCL and included unpublished cases diagnosed at our institutions to further characterize this disease subset. Based on our analysis of 356 cases of CD5-negative MCL, we conclude that median overall survival exceeds 14 years and is independent of favorable prognostic markers such as leukemic non-nodal disease, absence of SOX11, and low Ki-67.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.